BioWorld

Jan. 21, 2003

Amgen Hits Endpoints In First Enbrel Psoriasis Phase III Trial

The first of two Enbrel Phase III trials in psoriasis hit its primary and secondary endpoints, pushing Amgen Inc. to the halfway point in its quest to grow the blockbuster drug through the addition of another large market. (BioWorld Today) Read More

NPS's Phase III Bone Treatment Tested In Shuttle's Microgravity

FDA's Authority Over Cloning Questioned At Council Meeting

Holiday Notice

BioWorld's offices were closed Monday in observance of the Martin Luther King Jr. holiday in the U.S. No issue was published that day. Read More

Amylin Sells 9.2M Shares, Raises $152.7M For Symlin

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Medical illustration showing layers of a blood vessel

Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

BioWorld Science

More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...

Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

BioWorld Science

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...